CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going (December 2019)

Friday, December 6, 2019 in Orlando, Florida
Dinner -- Hyatt Regency Orlando, 6:00 PM ET
Regency Ballroom S, Convention Level


Pre-registration is now closed. We welcome you to register on-site at the Hyatt Regency Orlando, (9801 International Drive) Regency Ballroom S, Convention Level at 6:00 PM. Remember to bring your ASH conference badge to expedite your registration.


Program Director
Stephen J. Schuster

Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma
Division of Hematology/Oncology
Department of Medicine
University of Pennsylvania
Director, Lymphoma Program and Lymphoma Translational Research
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Matthew Frigault, MD

Instructor of Medicine
Division of Oncology
Department of Internal Medicine
Harvard Medical School
Clinical Assistant
Hematopoietic Cell Transplant and Cellular Therapy Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Jim Kochenderfer, MD

Investigator, Security Branch
National Cancer Institute
Bethesda, Maryland

Jae Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in integrating CAR T-cell therapy into the treatment of patients with leukemia, lymphoma, and myeloma.

Target Audience 
This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Learning Objectives

  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cell
  • Identify characteristics of patients that are appropriate for treatment with CAR T-cell therapy
  • Review the clinical trial data of CAR T-cell–based therapies for the treatment of leukemia and lymphoma patients, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Recall ongoing clinical trials evaluating CAR T-cell therapy for the treatment of leukemia, lymphoma, and myeloma to aid referral of appropriate patients


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.